Immunogenicity and pharmacokinetics of guselkumab among patients with moderate-to-severe psoriasis in VOYAGE-1 and VOYAGE-2
| Medienart: |
E-Artikel |
|---|
| Erscheinungsjahr: |
2023 |
|---|---|
| Erschienen: |
2023 |
| Enthalten in: |
Zur Gesamtaufnahme - volume:37 |
|---|---|
| Enthalten in: |
Journal of the European Academy of Dermatology and Venereology : JEADV - 37(2023), 12 vom: 01. Dez., Seite e1375-e1379 |
| Sprache: |
Englisch |
|---|
| Beteiligte Personen: |
Armstrong, A [VerfasserIn] |
|---|
| Links: |
|---|
| Themen: |
089658A12D |
|---|
| Anmerkungen: |
Date Completed 29.11.2023 Date Revised 29.11.2023 published: Print-Electronic Citation Status MEDLINE |
|---|
| doi: |
10.1111/jdv.19309 |
|---|
| funding: |
|
|---|---|
| Förderinstitution / Projekttitel: |
|
| PPN (Katalog-ID): |
NLM359166695 |
|---|
| LEADER | 01000naa a22002652 4500 | ||
|---|---|---|---|
| 001 | NLM359166695 | ||
| 003 | DE-627 | ||
| 005 | 20231226080310.0 | ||
| 007 | cr uuu---uuuuu | ||
| 008 | 231226s2023 xx |||||o 00| ||eng c | ||
| 024 | 7 | |a 10.1111/jdv.19309 |2 doi | |
| 028 | 5 | 2 | |a pubmed24n1197.xml |
| 035 | |a (DE-627)NLM359166695 | ||
| 035 | |a (NLM)37415560 | ||
| 040 | |a DE-627 |b ger |c DE-627 |e rakwb | ||
| 041 | |a eng | ||
| 100 | 1 | |a Armstrong, A |e verfasserin |4 aut | |
| 245 | 1 | 0 | |a Immunogenicity and pharmacokinetics of guselkumab among patients with moderate-to-severe psoriasis in VOYAGE-1 and VOYAGE-2 |
| 264 | 1 | |c 2023 | |
| 336 | |a Text |b txt |2 rdacontent | ||
| 337 | |a ƒaComputermedien |b c |2 rdamedia | ||
| 338 | |a ƒa Online-Ressource |b cr |2 rdacarrier | ||
| 500 | |a Date Completed 29.11.2023 | ||
| 500 | |a Date Revised 29.11.2023 | ||
| 500 | |a published: Print-Electronic | ||
| 500 | |a Citation Status MEDLINE | ||
| 650 | 4 | |a Letter | |
| 650 | 7 | |a guselkumab |2 NLM | |
| 650 | 7 | |a 089658A12D |2 NLM | |
| 650 | 7 | |a Antibodies, Monoclonal, Humanized |2 NLM | |
| 650 | 7 | |a Adalimumab |2 NLM | |
| 650 | 7 | |a FYS6T7F842 |2 NLM | |
| 700 | 1 | |a Eyerich, K |e verfasserin |4 aut | |
| 700 | 1 | |a Conrad, C |e verfasserin |4 aut | |
| 700 | 1 | |a Zhu, Y |e verfasserin |4 aut | |
| 700 | 1 | |a Yang, Y-W |e verfasserin |4 aut | |
| 700 | 1 | |a Miller, M |e verfasserin |4 aut | |
| 700 | 1 | |a You, Y |e verfasserin |4 aut | |
| 700 | 1 | |a Shen, Y-K |e verfasserin |4 aut | |
| 700 | 1 | |a Foley, P |e verfasserin |4 aut | |
| 700 | 1 | |a Griffiths, C E M |e verfasserin |4 aut | |
| 700 | 1 | |a Strober, B |e verfasserin |4 aut | |
| 773 | 0 | 8 | |i Enthalten in |t Journal of the European Academy of Dermatology and Venereology : JEADV |d 1997 |g 37(2023), 12 vom: 01. Dez., Seite e1375-e1379 |w (DE-627)NLM091705932 |x 1468-3083 |7 nnns |
| 773 | 1 | 8 | |g volume:37 |g year:2023 |g number:12 |g day:01 |g month:12 |g pages:e1375-e1379 |
| 856 | 4 | 0 | |u http://dx.doi.org/10.1111/jdv.19309 |3 Volltext |
| 912 | |a GBV_USEFLAG_A | ||
| 912 | |a GBV_NLM | ||
| 951 | |a AR | ||
| 952 | |d 37 |j 2023 |e 12 |b 01 |c 12 |h e1375-e1379 | ||